Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KELLY R AMANN

Allopathic & Osteopathic Physicians Family Medicine

NPI
1134116783
CMS profile
187578
Location
ROY, UT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$352.65

23 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $352.65 23

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KELLY R AMANN

NPI 1134116783 · CMS profile ID 187578

Allopathic & Osteopathic Physicians / Family Medicine

ROY, UT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1134116783?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KELLY R AMANN, NPI 1134116783, CMS profile ID 187578. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1134116783?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). KELLY R AMANN, NPI 1134116783, CMS profile ID 187578. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1134116783?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
KELLY R AMANN, NPI 1134116783, CMS profile ID 187578, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1134116783?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

23 matching records · $352.65 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 23 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–23 of 23.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech USA, Inc. $17.2812/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 857147265 CMS
Eisai Inc. $12.8312/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751244311 CMS
Amarin Pharma Inc. $15.6912/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740071717 CMS
Amarin Pharma Inc. $18.0011/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739929253 CMS
Amarin Pharma Inc. $18.9511/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739952083 CMS
QIAGEN, LLC $14.5610/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752481511 CMS
AstraZeneca Pharmaceuticals LP $11.5610/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735825927 CMS
Vanda Pharmaceuticals Inc. $26.2010/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735124293 CMS
Amarin Pharma Inc. $17.1810/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740071719 CMS
Astellas Pharma US Inc $13.4009/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718294175 CMS
Amarin Pharma Inc. $16.8309/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739948073 CMS
QIAGEN, LLC $14.0209/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752480359 CMS
Amarin Pharma Inc. $22.9208/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740071715 CMS
GlaxoSmithKline, LLC. $11.6207/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738968269 CMS
Eisai Inc. $11.1407/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751212307 CMS
Teva Pharmaceuticals USA, Inc. $13.4607/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749484505 CMS
GlaxoSmithKline, LLC. $17.4303/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738855539 CMS
Amgen Inc. $11.3603/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741174413 CMS
Lilly USA, LLC $11.4003/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728505817 CMS
Takeda Pharmaceuticals U.S.A., Inc. $12.5602/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747118571 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.0602/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720643115 CMS
AstraZeneca Pharmaceuticals LP $12.6902/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736372911 CMS
SANOFI-AVENTIS U.S. LLC $13.5101/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744181913 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $481.24 35
PY2020 $352.65 23
PY2021 $704.02 48
PY2022 $510.64 34
PY2023 $475.66 30
PY2024 $710.07 47
PY2025 $468.94 28

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $267,494.93 21
PY2024 Principal investigator $509,633.49 63
PY2023 Principal investigator $838,851.01 43

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

63 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $23,390.00 12/04/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 No dispute reported 06/30/2026 1110844994
Principal investigator 1 Genentech, Inc. $1,458.00 11/27/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388860
Principal investigator 1 Genentech, Inc. $1,965.00 11/27/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388920
Principal investigator 1 ModernaTX, Inc. $3,000.00 11/20/2024 Non-covered Recipient Entity
Ogden Clinic - Grand View
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147174631
Principal investigator 1 ModernaTX, Inc. $21,352.16 11/20/2024 Non-covered Recipient Entity
Ogden Clinic - Grand View
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147174635
Principal investigator 1 ModernaTX, Inc. $4,000.00 11/20/2024 Non-covered Recipient Entity
Ogden Clinic - Grand View
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147174639
Principal investigator 1 ModernaTX, Inc. $750.00 11/20/2024 Non-covered Recipient Entity
Ogden Clinic - Grand View
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147174644
Principal investigator 1 ModernaTX, Inc. $2,000.00 11/20/2024 Non-covered Recipient Entity
Ogden Clinic - Grand View
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147174648
Principal investigator 1 ModernaTX, Inc. $2,000.00 11/20/2024 Non-covered Recipient Entity
Ogden Clinic - Grand View
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147174652
Principal investigator 1 ModernaTX, Inc. $1,500.00 11/20/2024 Non-covered Recipient Entity
Ogden Clinic - Grand View
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147174656
Principal investigator 1 ModernaTX, Inc. $1,150.00 11/20/2024 Non-covered Recipient Entity
Ogden Clinic - Grand View
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147174660
Principal investigator 1 AstraZeneca Pharmaceuticals LP $28,900.00 11/13/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1110846857
Principal investigator 1 Genentech, Inc. $1,431.00 11/13/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388938
Principal investigator 1 Genentech, Inc. $527.00 10/30/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388974
Principal investigator 1 Genentech, Inc. $1,054.00 10/23/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388906
Principal investigator 1 Genentech, Inc. $527.00 10/09/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388892
Principal investigator 1 ModernaTX, Inc. $8,264.09 10/09/2024 Non-covered Recipient Entity
Ogden Clinic - Grand View
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147174603
Principal investigator 1 Genentech, Inc. $1,054.00 10/04/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388890
Principal investigator 1 Exact Sciences Corporation $1,000.00 10/02/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
Informed Choice Intervention for Colorectal Cancer Screening No dispute reported 06/30/2026 1140222013
Principal investigator 1 Genentech, Inc. $540.00 09/25/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388846
Principal investigator 1 Genentech, Inc. $143.00 09/06/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388702
Principal investigator 1 ModernaTX, Inc. $2,277.08 09/06/2024 Non-covered Recipient Entity
Ogden Clinic - Grand View
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147174514
Principal investigator 1 ModernaTX, Inc. $2,000.00 09/06/2024 Non-covered Recipient Entity
Ogden Clinic - Grand View
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147174517
Principal investigator 1 ModernaTX, Inc. $2,100.00 09/06/2024 Non-covered Recipient Entity
Ogden Clinic - Grand View
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147174521
Principal investigator 1 ModernaTX, Inc. $2,000.00 09/06/2024 Non-covered Recipient Entity
Ogden Clinic - Grand View
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147174526
Principal investigator 1 ModernaTX, Inc. $2,680.00 09/03/2024 Non-covered Recipient Entity
Ogden Clinic - Grand View
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147174529
Principal investigator 1 ModernaTX, Inc. $2,000.00 09/03/2024 Non-covered Recipient Entity
Ogden Clinic - Grand View
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147174534
Principal investigator 1 Mylan Specialty L.P. $5,500.00 08/26/2024 Non-covered Recipient Entity
Ogden Clinic
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel?Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 1141407779
Principal investigator 1 Genentech, Inc. $670.00 08/16/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388834
Principal investigator 1 ModernaTX, Inc. $42,047.23 08/09/2024 Non-covered Recipient Entity
Ogden Clinic - Grand View
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147174501
Principal investigator 1 ModernaTX, Inc. $1,340.00 08/09/2024 Non-covered Recipient Entity
Ogden Clinic - Grand View
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147174506
Principal investigator 1 Genentech, Inc. $750.00 08/07/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388718
Principal investigator 1 Genentech, Inc. $2,349.00 08/07/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388720
Principal investigator 1 ModernaTX, Inc. $1,375.00 08/07/2024 Non-covered Recipient Entity
Ogden Clinic - Grand View
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147174510
Principal investigator 1 Exact Sciences Corporation $1,242.00 08/02/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
Informed Choice Intervention for Colorectal Cancer Screening No dispute reported 06/30/2026 1140222005
Principal investigator 1 Genentech, Inc. $162.00 08/02/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388786
Principal investigator 1 Genentech, Inc. $2,349.00 07/10/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388808
Principal investigator 1 ModernaTX, Inc. $750.00 07/01/2024 Non-covered Recipient Entity
Ogden Clinic - Grand View
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147174453
Principal investigator 1 ModernaTX, Inc. $8,650.00 07/01/2024 Non-covered Recipient Entity
Ogden Clinic - Grand View
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147174457
Principal investigator 1 AstraZeneca Pharmaceuticals LP $42,637.05 06/14/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1110841534
Principal investigator 1 Genentech, Inc. $1,182.00 06/14/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388494
Principal investigator 1 Genentech, Inc. $900.00 06/07/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388490
Principal investigator 1 Genentech, Inc. $2,349.00 06/07/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388604
Principal investigator 1 Exact Sciences Corporation $2,000.00 06/05/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
Informed Choice Intervention for Colorectal Cancer Screening No dispute reported 06/30/2026 1140222011
Principal investigator 1 AstraZeneca Pharmaceuticals LP $33,067.44 05/31/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) No dispute reported 06/30/2026 1110838298
Principal investigator 1 Genentech, Inc. $50.00 05/31/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388412
Principal investigator 1 Genentech, Inc. $135.00 05/24/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388504
Principal investigator 1 Genentech, Inc. $600.00 05/22/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388512
Principal investigator 1 Genentech, Inc. $750.00 05/15/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388592
Principal investigator 1 Genentech, Inc. $945.00 04/24/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388416
Principal investigator 1 Exact Sciences Corporation $571.32 03/20/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
Informed Choice Intervention for Colorectal Cancer Screening No dispute reported 06/30/2026 1140222003
Principal investigator 1 ModernaTX, Inc. $3,500.00 03/20/2024 Non-covered Recipient Entity
Ogden Clinic - Grand View
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147174373
Principal investigator 1 ModernaTX, Inc. $23,535.60 03/15/2024 Non-covered Recipient Entity
Ogden Clinic - Grand View
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147174405
Principal investigator 1 Exact Sciences Corporation $1,785.72 03/06/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
Informed Choice Intervention for Colorectal Cancer Screening No dispute reported 06/30/2026 1140222009
Principal investigator 1 ModernaTX, Inc. $182.25 02/28/2024 Non-covered Recipient Entity
Ogden Clinic - Grand View
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147174304
Principal investigator 1 Exact Sciences Corporation $1,000.00 02/07/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
Informed Choice Intervention for Colorectal Cancer Screening No dispute reported 06/30/2026 1140222001
Principal investigator 1 Genentech, Inc. $7,047.00 02/07/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388250
Principal investigator 1 ModernaTX, Inc. $132,058.70 02/07/2024 Non-covered Recipient Entity
Ogden Clinic - Grand View
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147174365
Principal investigator 1 ModernaTX, Inc. $59,415.60 02/07/2024 Non-covered Recipient Entity
Ogden Clinic - Grand View
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147174369
Principal investigator 1 Genentech, Inc. $750.00 01/24/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388334
Principal investigator 1 ModernaTX, Inc. $1,208.25 01/19/2024 Non-covered Recipient Entity
Ogden Clinic - Grand View
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147174296
Principal investigator 1 Abbott Laboratories $7,500.00 01/05/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
COVID-19/Flu Sample Collection No dispute reported 06/30/2026 1146159520
Principal investigator 1 Mylan Specialty L.P. $217.00 01/05/2024 Non-covered Recipient Entity
Ogden Clinic
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel?Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 1141407775